Log in

NASDAQ:AMRS - Amyris Stock Price, Forecast & News

$2.97
-0.12 (-3.88 %)
(As of 01/19/2020 01:41 PM ET)
Today's Range
$2.91
Now: $2.97
$3.13
50-Day Range
$2.85
MA: $3.27
$4.02
52-Week Range
$1.87
Now: $2.97
$6.06
Volume2.52 million shs
Average Volume1.51 million shs
Market Capitalization$313.34 million
P/E RatioN/A
Dividend YieldN/A
Beta0.89
Amyris, Inc, an integrated renewable products company, delivers alternatives to petroleum, plant, and animal-based products across a range of consumer and industry segments worldwide. It applies its bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients, and consumer products. The company delivers its No Compromise products and services in markets, such as specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals. Read More…

Industry, Sector and Symbol

Industry Industrial organic chemicals
Sub-IndustryOil & Gas Refining & Marketing
SectorBasic Materials
Current SymbolNASDAQ:AMRS
CUSIP03236M10
Phone510-450-0761

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$80.42 million
Book Value($2.83) per share

Profitability

Net Income$-230,240,000.00
Net Margins-161.48%

Miscellaneous

Employees414
Market Cap$313.34 million
Next Earnings Date3/16/2020 (Estimated)
OptionableOptionable

Receive AMRS News and Ratings via Email

Sign-up to receive the latest news and ratings for AMRS and its competitors with MarketBeat's FREE daily newsletter.


(Ad)


Its partners include AT&T, Verizon, Sprint and T-Mobile.

It owns more than 200 patents.

And analysts say it has "home-run potential."

Yet this 5G superstock trades for only $5 a share.

Amyris (NASDAQ:AMRS) Frequently Asked Questions

What is Amyris' stock symbol?

Amyris trades on the NASDAQ under the ticker symbol "AMRS."

When did Amyris' stock split? How did Amyris' stock split work?

Amyris shares reverse split on Tuesday, June 6th 2017. The 1-15 reverse split was announced on Tuesday, June 6th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 5th 2017. An investor that had 100 shares of Amyris stock prior to the reverse split would have 7 shares after the split.

How were Amyris' earnings last quarter?

Amyris Inc (NASDAQ:AMRS) released its quarterly earnings results on Thursday, November, 7th. The biotechnology company reported ($0.51) EPS for the quarter, beating the Zacks' consensus estimate of ($0.53) by $0.02. The biotechnology company had revenue of $34.95 million for the quarter, compared to analysts' expectations of $21.60 million. View Amyris' Earnings History.

When is Amyris' next earnings date?

Amyris is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Amyris.

What guidance has Amyris issued on next quarter's earnings?

Amyris issued an update on its FY 2019 After-Hours earnings guidance on Monday, November, 25th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $$150 million, compared to the consensus revenue estimate of $$148.65 million.

What price target have analysts set for AMRS?

2 equities research analysts have issued 12-month price targets for Amyris' shares. Their forecasts range from $8.00 to $11.00. On average, they expect Amyris' stock price to reach $9.50 in the next year. This suggests a possible upside of 219.9% from the stock's current price. View Analyst Price Targets for Amyris.

What is the consensus analysts' recommendation for Amyris?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amyris in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Amyris.

Has Amyris been receiving favorable news coverage?

News headlines about AMRS stock have been trending neutral on Sunday, according to InfoTrie. The research group identifies positive and negative news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Amyris earned a media sentiment score of 0.2 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Amyris.

Are investors shorting Amyris?

Amyris saw a increase in short interest in December. As of December 31st, there was short interest totalling 17,190,000 shares, an increase of 11.7% from the December 15th total of 15,390,000 shares. Based on an average daily trading volume, of 1,040,000 shares, the short-interest ratio is currently 16.5 days. Approximately 31.4% of the shares of the stock are short sold. View Amyris' Current Options Chain.

Who are some of Amyris' key competitors?

What other stocks do shareholders of Amyris own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amyris investors own include Gevo (GEVO), Keryx Biopharmaceuticals (KERX), Canopy Growth (CGC), Advanced Micro Devices (AMD), Corbus Pharmaceuticals (CRBP), Intel (INTC), Novavax (NVAX), General Electric (GE), Inovio Pharmaceuticals (INO) and Amarin (AMRN).

Who are Amyris' key executives?

Amyris' management team includes the folowing people:
  • Mr. John G. Melo, Pres, CEO & Director (Age 53)
  • Ms. Kathleen Valiasek, Chief Financial Officer (Age 55)
  • Mr. Eduardo Alvarez, Chief Operating Officer (Age 55)
  • Ms. Nicole Kelsey, Gen. Counsel & Sec. (Age 52)
  • Dr. Joel R. Cherry, Pres of R&D (Age 58)

How do I buy shares of Amyris?

Shares of AMRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Amyris' stock price today?

One share of AMRS stock can currently be purchased for approximately $2.97.

How big of a company is Amyris?

Amyris has a market capitalization of $313.34 million and generates $80.42 million in revenue each year. The biotechnology company earns $-230,240,000.00 in net income (profit) each year or ($2.53) on an earnings per share basis. Amyris employs 414 workers across the globe.View Additional Information About Amyris.

What is Amyris' official website?

The official website for Amyris is http://amyris.com/.

How can I contact Amyris?

Amyris' mailing address is 5885 HOLLIS STREET SUITE 100, EMERYVILLE CA, 94608. The biotechnology company can be reached via phone at 510-450-0761 or via email at [email protected]


MarketBeat Community Rating for Amyris (NASDAQ AMRS)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  297 (Vote Outperform)
Underperform Votes:  448 (Vote Underperform)
Total Votes:  745
MarketBeat's community ratings are surveys of what our community members think about Amyris and other stocks. Vote "Outperform" if you believe AMRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMRS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/19/2020 by MarketBeat.com Staff

Featured Article: Quiet Period

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel